NewAmsterdam Pharma Company N. V. , a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
Newamsterdam Pharma Co Nv stock last closed at $34.74, down 0.8% from the previous day, and has increased 35.7% in one year. It has overperformed other stocks in the Biotechnology industry by 0.78 percentage points. Newamsterdam Pharma Co Nv stock is currently +147.08% from its 52-week low of $14.06, and -17.29% from its 52-week high of $42.00.
There are currently 113.39M shares of NAMS outstanding. The market cap of NAMS is $3.94B. In the past 24 hours, 765,000 NAMS shares were traded.
How to Buy Newamsterdam Pharma Co Nv Stock
Not sure how to invest in Newamsterdam Pharma Co Nv stock? Here's how.
Figure out where to buy Newamsterdam Pharma Co Nv stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you choose where to buy Newamsterdam Pharma Co Nv stock.
Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
Put funds into your brokerage account: Select your method of payment and add your info.
Analyze Newamsterdam Pharma Co Nv stock: The Newamsterdam Pharma Co Nv ticker symbol is NAMS. Is Newamsterdam Pharma Co Nv stock a good investment? Should you buy shares of NAMS? How do NAMS's underlying business fundamentals look? Do top analysts think Newamsterdam Pharma Co Nv is a good buy? Why has NAMS's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if NAMS is a good stock to buy).
Make your NAMS purchase: Decide if you will purchase NAMS shares at the current market price or use a limit order to purchase NAMS shares at a particular price.
Get key alerts regarding your NAMS investment: Create a watchlist to monitor your investment in Newamsterdam Pharma Co Nv shares.
Step 1: Figure out where to buy Newamsterdam Pharma Co Nv stock
You need a brokerage account in order to access the NASDAQ market and buy NAMS stock.
A brokerage account is an investment account that allows you to buy and sell a number of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to world financial markets: From Technology to Industrials, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal information so you can buy NAMS today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Newamsterdam Pharma Co Nv stock
After you have identified the best place to buy Newamsterdam Pharma Co Nv stock, it's crucial to research their stock before you invest, so you actually understand the risk as well as the upside.
Newamsterdam Pharma Co Nv shares at a glance
NAMS Price
$34.74
1w %
-3.37%
1y %
35.7%
5y %
231.49%
P/E
-14.57x
P/B
4.65x
P/S
96.23x
PEG
N/A
Revenue
$40.98M
Earnings
-$257.06M
Fore. Rev. Growth
57.2%
Fore. Earn. Growth
N/A
Market Cap
$3.94B
Next Earnings
N/A
Next Dividend
N/A
NAMS Fundamentals
WallStreetZen was built to help part-time investors perform better fundamental analysis.
NAMS has cash burn of 168067441. It has enough cash and short-term investments to cover this for at least one year.
There are more short-term assets than short-term liabilities on the NAMS balance sheet.
NAMS has a low debt to equity ratio of 0.08.
Total NAMS debt is lower than 5 years ago, relative to shareholder equity.
There are more short-term assets than long-term liabilities on the NAMS balance sheet.
Failed Financial Due Diligence Checks:
NAMS profit margin has gone down from -592.1% to -627.3% in the past year.
NAMS has $818.90M in cash and short term investments. This is not enough to cover its annual cash burn of $168.07M.
Is NAMS stock a Buy, Hold, or Sell, according to analysts?
Out of 7 sell side analysts who give ratings on NAMS, the consensus analyst rating on Newamsterdam Pharma Co Nv is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
Most Recent NAMS Analyst Forecasts
Geoff Meacham, a top 12% analyst from Citigroup maintains NAMS with a strong buy rating and raises their NAMS price target from $42.00 to $50.00, on Oct 17, 2025.
Citigroup's Geoff Meacham raised their price target on Newamsterdam Pharma Co Nv (NASDAQ: NAMS) by 19% from $42 to $50 on 2025/10/17. The analyst maintained their Strong Buy rating on the stock.
Newamsterdam Pharma Co NV is expected to report its Q3 2025 earnings on 2025/11/17.
Meacham's price target hike was part of a Q3 2025 pre-print review of names in their Biotechnology portfolio.
According to the analyst, smaller-sized biotech stocks are starting to attract investor interest, which could bode well for the group in 2026.
Yanan Zhu, a top 21% analyst from Wells Fargo initiates coverage on NAMS with a strong buy rating and announces their NAMS price target of $45.00, on Aug 25, 2025.
Last year, NAMS revenue was $40.98M. During the past 1 years, NAMS's revenue has increased by 11.08% per year. This was slower than the Biotechnology industry average of 44.64%.
In the past 12 months, insiders at NAMS have bought more shares than they have sold.
Louise Frederika Kooij, Chief Accounting Officer of NAMS, was the latest NAMS insider to buy. They bought $388,720.00 worth of NAMS shares on Dec 26, 2025.
No, Newamsterdam Pharma Co Nv doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your NAMS purchase
You have two primary options:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are usually sufficient.
Limit order: A limit order allows you to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at a given dollar amount, use a limit order.
Press the Open Trade button and eToro will execute the order.
If you need additional info about investing in stocks on eToro, click the how to video below:
How much does it cost to buy one Newamsterdam Pharma Co Nv share?
As of Dec 30, 2025, it costs $34.74 to buy one share of Newamsterdam Pharma Co Nv stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.288 shares of NAMS.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.